1
INTRODUCTION 20
Clostridioides (formerly Clostridium) difficile is the most commonly recognized cause of 21 infectious diarrhea in healthcare settings, and is the most commonly reported pathogen among 22 healthcare-associated infections of adults in the United States (1) . However, asymptomatic 23 colonization has been found in acute care hospitals at an incidence of 3%-26% in adult inpatients 24 (2) (3) (4) . Differentiating patients who are colonized from those who have active CDI remains a 25 diagnostic challenge. While NAAT has a high clinical sensitivity, its clinical specificity is 26 suboptimal for diagnosing patients who have CDI (5) . An array of algorithms and protocols have 27 been created to improve diagnostic accuracy of CDI. 28
The 2017 Infectious Disease Society of America (IDSA) and Society for Healthcare 29
Epidemiology of America (SHEA) guidelines for C. difficile recommend the use of a stool toxin 30 test as a part of a multistep algorithm (i.e. GDH plus toxin; GDH plus toxin, arbitrated by NAAT; or 31 NAAT plus toxin) at institutions without a formal process to submit stool specimens from only 32 patients with unexplained new onset diarrhea with 3 or more unformed stools in a 24 hour period. 33
At institutions that do have a policy to only submit stool for C. difficile testing in patients with 3 or 34 more unformed stools in a 24-hour period, testing by NAAT alone is provided as an alternative 35 diagnostic option (6) . 36
Accurate diagnosis of CDI is essential. A false positive test result would lead to unnecessary 37 antibiotic exposure and increases in costs of care, while missing a diagnosis of CDI would likely 38 lead to increased morbidity and mortality. We undertook this study to evaluate the impact of 39 adding toxin testing to NAAT to differentiate colonization from CDI (7) . 40
41

METHODS 42
This study was performed at a 500-bed, tertiary care, academic medical center in the 43 Midwestern United States. As part of routine diagnostic workup for CDI, unformed stool 44 specimens were submitted to the clinical microbiology laboratory to detect the presence of C. 45 difficile toxin B gene via the Xpert C. difficile/Epi NAAT (Cepheid, Sunnyvale, CA). For this study, 46 unformed stool samples, nonselectively chosen based on investigator availability from January to 47
May 2017, were subsequently tested with the TECHLAB C. DIFF QUIK CHEK COMPLETE EIA 48 (TECHLAB, Blacksburg, VA) according to manufacturer instructions to evaluate for the presence 49 of GDH, and toxins A and B. 50
Two infectious disease physicians independently reviewed electronic medical records of the 51 corresponding patients. Reviewers were blinded to the EIA results and to each other's 52 assessment. Blinding for NAAT results was not possible since the results could be readily seen 53 within the patients' electronic medical records. The following criteria adapted and modified from 54 the 2010 IDSA guidelines were utilized by the reviewers in assessing disease status: presence of 55 diarrhea defined as 3 or more unformed stools within a 24-hour period, antibiotic use within 90 56 days of symptom onset, prior history of CDI, improvement of symptoms with CDI treatment, and 57 colonoscopy findings, if performed (8, 9) . Since there is no gold standard for diagnosing CDI, 58 each reviewer used the constellation of above factors, along with their clinical judgment to group 59 patients into one of three categories: (1) CDI-Likely, (2) CDI-Unlikely, and (3) CDI-Indeterminate. 60
Clinical sensitivity and specificity were calculated using 3 definitions of "true" CDI status: [1] both 61 reviewers were concordant in assigning CDI-Likely or CDI-Unlikely to a patient (CDI-62
Indeterminate results were excluded in this calculation); [2] both reviewers were concordant in 63 assigning CDI-Likely or CDI-Unlikely, and remaining patients (CDI-Indeterminate and discordant 64 categorization) were included in the CDI-Likely group; and [3] both reviewers were concordant in 65 assigning CDI-Likely or CDI-Unlikely, and remaining patients (CDI-Indeterminate and discordant 66 categorization) were included in the CDI-Unlikely group. 67 68 RESULTS 69 59 patients were included in this study. Independent categorization of CDI status by two 70 infectious disease specialists is shown in Table 1 . Overall percent agreement between the 71 reviewers was 78% (46 of 59 concordant), and Kappa was 0.64 (95% confidence interval 0.47-72 0.80). Notably, Reviewer 1 categorized more patients as CDI-Likely (n=35) than Reviewer 2 73 (n=26), while Reviewer 2 categorized more patients as CDI-Indeterminate (n=12) than Reviewer 74 1 (n=4). Both reviewers had a similar number of CDI-Unlikely patients (n=20 and n=21). Patient 75 age and gender were similarly distributed among each CDI status group; median age was 60 76 years (ranging 1 to 97 years) and there were 58% (n=34) males ( Table 2) . NAAT was positive in 77 71% (42 of 59) of patients, GDH EIA in 66% (37 of 56), and Toxin EIA in 27% (16 of 59); the 78 results of 3 GDH EIA tests could not be retrieved (Table 3 ). Of CDI-Likely patients, 58% (14 of 79 24) were Toxin EIA-negative. Of NAAT-positive specimens, 62% (26 of 42) were Toxin EIA-80 negative, and 85% (22 of 26) of these patients symptomatically benefited from treatment for CDI. 81
There were no (0%) instances where GDH EIA and/or Toxin EIA was positive and NAAT was 82 negative. Using 3 different definitions of "true" CDI status, clinical sensitivity and specificity for 83
NAAT was 100% and 49-94%, GDH EIA was 83-85% and 43-89%, and Toxin EIA was 39-42% 84 and 83-100%, respectively (Table 4) . 85 86 DISCUSSION 87
The high sensitivity of NAAT in diagnosing CDI has been well documented (5) . This attribute 88 has been instrumental in directing CDI treatment and avoiding progression of disease for patients 89 with true CDI. However, it is also recognized that molecular tests may lead to overdiagnosis of 90 CDI due to suboptimal clinical specificity and result in increases in both direct and indirect costs 91 related to unnecessary treatment and isolation precautions, overutilization of infection prevention 92 and control resources, and reporting of inflated CDI rates (10) (11) (12) (13) . Furthermore, CDI treatment 93 with antibiotics has been reported to increase the risk of vancomycin-resistant enterococci (14, 94 15) . Because of this, supplementation of NAAT with Toxin EIA as part of a 2-step testing 95 algorithm has been proposed by IDSA/SHEA and European Society of Clinical Microbiology and 96
Infectious Diseases guidelines (6, 16) . Prior studies have reported that performing both NAAT 97
and Toxin EIA may provide clinically useful information. For instance, patients with diarrhea who 98 are NAAT-positive but Toxin EIA-negative may not develop adverse outcomes, even without 99 specific therapy for CDI (17) . Also, recurrence of CDI may be more common when both NAAT 100 and toxin assays are positive than when NAAT alone is positive (17) . And, complications are 101 more common among patients who are positive by both NAAT and a 3-step algorithm -including 102 GDH, toxins A and B, and cell culture cytotoxicity assay -than when NAAT alone is positive (18) . 103
Nevertheless, others have found that addition of Toxin EIA to NAAT does not reliably 104 distinguish patients with CDI from those who are colonized. Rios et al. found that 75% of their 105 NAAT-positive specimens were Toxin EIA-negative, and that Toxin EIA-negative results were 106 seen just as frequently in CDI as in colonized patients with positive NAAT results (19) . We 107 similarly found that most (62%) NAAT-positive specimens were Toxin-EIA-negative, and most 108 (85%) of these patients still benefited symptomatically from CDI treatment. Toxin-EIA results were 109 not contributory to the diagnosis of CDI, because of CDI-Likely patients, Toxin-EIA was negative 110 in 58%. Consistent with this, informal polling (data not shown) of healthcare providers at our 111 institution revealed that virtually all would treat for CDI if it was in the differential diagnosis and the 112 patient had a positive NAAT result, regardless of the Toxin-EIA result. 113
Because there is currently no gold standard for the diagnosis of CDI, assay performance is 114 particularly challenging to assess. When defining "true positives" and "true negatives" as 115 concordance between both reviewers in categorizing patients as CDI-Likely and CDI-Unlikely, 116 respectively, NAAT performed well (clinical sensitivity 100% and specificity 94%). However, when 117 applying this definition, which uses only the most clinically apparent CDI patients, Toxin EIA had 118 low clinical sensitivity (42%). When including CDI-Indeterminate patients and patients that had 119 discordant categorization into the "true positives", the clinical sensitivities and specificities of 120 NAAT and Toxin EIA were essentially unchanged; however, when including CDI-121 Indeterminate/discordant patients as "true negatives", clinical specificity of NAAT dropped 122 markedly (94% to 49%), and it also decreased for Toxin EIA (100% to 83%). Regardless of how 123 "true" CDI status was defined, the clinical sensitivity of Toxin EIA (range of 39-42%) clearly 124 demonstrated a need for improvement, which was consistent with the findings of others (15, 19, 125 20) . 126
This study has several limitations. The lack of diagnostic gold standard for CDI resulted in 127 variability between the two reviewers when categorizing patients into the three different CDI 128 status groups. Upon unblinding, the discordant categorizations were thought to be attributable to 129 differences in interpretation of what constituted clinical improvement with treatment for CDI, and 130 lack of agreement as to whether or not the presence of a rectal tube was indicative of a patient 131 having 3 or more loose stools per day. Furthermore, due to the retrospective nature of this study, 132 it was challenging to obtain complete information from the medical records; in particular, 133 frequency of diarrhea, character of stools, and duration of symptoms prior to hospital presentation 134 were difficult to ascertain for some patients. Another limitation of this study was that specimen 135 selection was not completely randomized and was more dependent on when the investigator 136 performing EIA testing was available. Our sample set is likely enriched with NAAT-positive 137 patients; thus, the calculated clinical sensitivities and specificities may not be representative of an 138 unbiased population. 139
In summary, the diagnosis of CDI remains challenging, but the addition of Toxin EIA testing 140
to NAAT-positive specimens as part of a two-step diagnostic algorithm would provide minimal 141 clinical benefit. At our institution, we have implemented multiple layers of checks to optimize C. 142 difficile NAAT utilization, from decision support during ordering to rejection of formed stools during 143 laboratory receipt, and in this setting, NAAT testing alone is currently the best solution for our 144 healthcare system. 145 * GDH EIA results for 3 patients were unable to be retrieved, and all 3 had been categorized as CDI-Unlikely. Clinical specificity was consequently calculated first assuming all 3 GDH EIA results were positive, and second assuming all 3 GDH EIA results were negative.
